argenx SE (ARGX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Autoimmunesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 13/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.18% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR
- Is Expanded Argenx Deal Altering The Investment Case For Halozyme Therapeutics (HALO)?
- European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- Top biotechnology stock pick from Guggenheim
- European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
- argenx Meets Primary Endpoint in Phase II Celiac Disease Study
- European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
- Biological and clinical stability after switching from intravenous to subcutaneous natalizumab in RRMS under standard and extended dosing. — Front Immunol 2026 PMID 42558353
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial. — Nat Med 2026 Sep PMID 42557458
- FcRn inhibitors in the treatment of CIDP. — J Neurol Sci 2026 Oct 15 PMID 42456334
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. — Lancet Diabetes Endocrinol 2026 Aug PMID 42251860
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for argenx SE.
Full ARGX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.